Sort   by:  
 Page size 
Dendritic cell (DC) vaccines have been proposed as cancer immunotherapies due to their role as crucial antigen-presenting cells that regulate T cell functions. Despite considerable efforts to optimize ex vivo priming of DCs, DC vaccines have rarely been successful, suggesting the presence of unknown...
2025-11-03 | MTBLS10389 | MetaboLights

Adoptive T cell receptor (TCR)–based immunotherapy offers a powerful strategy to target solid tumors. However, the physical properties of the antigen-presenting interface regulate T cell metabolic programming remains poorly defined. Here we develop synthetic viscoelastic activating cells (SynVAC)...

2026-09-03 | MTBLS15444 | MetaboLights
The application of ketogenic diet (KD) (high fat/low carbohydrate/adequate protein) as an auxiliary cancer therapy is a field of growing attention. KD provides sufficient energy supply for healthy cells, while possibly impairing energy production in highly glycolytic tumor cells. Moreover, KD regula...
2019-10-08 | MTBLS1066 | MetaboLights
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, with chronic hepatitis B virus (HBV) infection being a major contributor to its development. Despite this, effective treatment for HBV-associated HCC remains a significant challenge. In this study, we combined the s...
2025-07-17 | MTBLS12196 | MetaboLights

This study investigates the proliferative effects of environmentally relevant exposure to butyl benzyl phthalate (BBP) on triple-negative breast cancer using integrated in vivo and in vitro approaches.

2025-12-06 | MTBLS13467 | MetaboLights
Stem cell antigen-1 (Sca-1 or Ly6A) is a member of the Ly6 family of glycosyl phostidylinositol (GPI)-anchored cell surface proteins. To determine the potential mechanisms by which Sca-1 regulates cell migration, adhesion, and tumor development; we performed an Affymetrix mouse genome 430A 2.0 array...
ORGANISM(S): Mus musculus 
Tumor mutational burden (TMB), usually representing high immunogenicity, could not always predict treatment response of immune checkpoint blockade (ICB). Here, we showed that defective antigen cross-presentation in type 1 conventional dendritic cells (cDC1) was responsible for lacking tumor-specific...
ORGANISM(S): Homo Sapiens 
Multi-drug resistance (MDR) is an almost inevitable end point of cancer therapy, driving rapid tumor progression, yet its evolutionary logic remains unclear because MDR tumors are rarely resected. Using paired therapy-naive and MDR melanoma specimens from a clinical trial, integrated with single-cel...
2027-08-13 | MTBLS15322 | MetaboLights
Tumors express a wide variety of both mutated and non-mutated antigens. Whether these tumor antigens are broadly recognized as “self” or “foreign” by the immune system is currently unclear. Using an autochthonous prostate cancer model in which hemagglutinin (HA) is specifically expressed in ...
ORGANISM(S): Mus musculus 

Small cell lung cancer (SCLC) exhibits profound immunometabolic suppression that impairs antigen presentation and constrains immunotherapy efficacy. Through integrated multi-omics analyses of primary human SCLC tumors, we identified midkine (MDK) as a dominant tumor-secreted driver of immune evas...

2026-03-23 | MTBLS14116 | MetaboLights
Sort   by:  
 Page size